Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics
View / Open Files
Ashford, Fiona B.
Jones, Ben J.
Lucey, Maria A.
Reissaus, Christopher A.
Nature Publishing Group UK
MetadataShow full item record
Ast, J., Arvaniti, A., Fine, N. H. F., Nasteska, D., Ashford, F. B., Stamataki, Z., Koszegi, Z., et al. (2020). Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics. Nature Communications, 11 (1)https://doi.org/10.1038/s41467-020-14309-w
Funder: U.S. Department of Health & Human Services | National Institutes of Health (NIH)
Funder: EC | EC Seventh Framework Programm | FP7 Ideas: European Research Council (FP7-IDEAS-ERC - Specific Programme: "Ideas" Implementing the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007 to 2013)); doi: https://doi.org/10.13039/100011199; Grant(s): 715884
Abstract: The glucagon-like peptide-1 receptor (GLP1R) is a class B G protein-coupled receptor (GPCR) involved in metabolism. Presently, its visualization is limited to genetic manipulation, antibody detection or the use of probes that stimulate receptor activation. Herein, we present LUXendin645, a far-red fluorescent GLP1R antagonistic peptide label. LUXendin645 produces intense and specific membrane labeling throughout live and fixed tissue. GLP1R signaling can additionally be evoked when the receptor is allosterically modulated in the presence of LUXendin645. Using LUXendin645 and LUXendin651, we describe islet, brain and hESC-derived β-like cell GLP1R expression patterns, reveal higher-order GLP1R organization including membrane nanodomains, and track single receptor subpopulations. We furthermore show that the LUXendin backbone can be optimized for intravital two-photon imaging by installing a red fluorophore. Thus, our super-resolution compatible labeling probes allow visualization of endogenous GLP1R, and provide insight into class B GPCR distribution and dynamics both in vitro and in vivo.
Article, /631/1647/245/2226, /631/80/2373/2238, /631/92/96, /692/163/2743, /14/69, /14/34, /96, /96/33, /96/100, /64/60, /13/51, /123, /14, /14/19, /14/63, /45, /38, /59, article
RCUK | Medical Research Council (MRC) (MR/R010676/1, MR/R010676/1, MR/N00275X/1, MR/S025618/1)
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre) (CIHR PJT 156377)
U.S. Department of Health & Human Services | National Institutes of Health (NIH) (UC4 DK104162, R01 DK095757)
Wellcome Trust (Wellcome) (212313/Z/18/Z)
RCUK | MRC | Medical Research Foundation (MR/N02589X/1)
Diabetes UK (12/0004431)
External DOI: https://doi.org/10.1038/s41467-020-14309-w
This record's URL: https://www.repository.cam.ac.uk/handle/1810/316627
Attribution 4.0 International (CC BY 4.0)
Licence URL: https://creativecommons.org/licenses/by/4.0/